ArriVent BioPharma reported collaboration revenue of $5.0 million for the nine months ended September 30, 2026, compared to zero in the prior year. Despite this, the company saw a net loss of $133.5 million driven by $118.9 million in research and development expenses. Cash and short-term investments increased to $393.2 million, bolstered by $199.6 million in net proceeds from common stock issuances.
ArriVent BioPharma reported Q3 2026 financial results, highlighting a cash position of $393.2 million and progress in its Phase 3 ALPACCA study. The company also announced the retirement of Stuart Lutzker, M.D., Ph.D., as President of R&D, with Chief Medical Officer Priti Patel, M.D., assuming leadership of the R&D function.
Term
Q3 2026
“Enrollment remains on track for our global Phase 3 ALPACCA trial in first line EGFR PACC mutant NSCLC patients. While FURVENT did not meet its primary endpoint, firmonertinib demonstrated clear antitumor activity, with an efficacy and safety profile consistent with prior studies.”